Correction: Wang, F.; Multhoff, G. Repurposing Cannabidiol as a Potential Drug Candidate for Anti-Tumor Therapies. Biomolecules 2021, 11, 582
Radiation-Immuno Oncology Group, TranslaTUM—Central Institute for Translational Cancer Research, Klinikum rechts der Isar, TU München, Einsteinstr. 25, 81675 Munich, Germany
Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China
Department of Radiation Oncology, Klinikum rechts der Isar, TU München, 81675 Munich, Germany
*Correspondence: feiwang615@gmail.com; Tel.: +49-89-4140-4514; Fax: +49-89-4140-4299There was a misplaced reference in the original article in the first paragraph of Section 6 “Clinical Trials with CBD” [1]. By misplacing reference 138 in the original article, an inaccurate interpretation of the study was made.
The amendment is listed below, to which in addition, a sentence has been removed in order to maintain the paragraph’s readability:
“Due to its non-psychoactive characteristics, CBD is superior to other cannabinoids in clinical applications. A double-blind, placebo-controlled, randomized clinical phase I trial has been started to prove its safety and capability to relieve tumor-related adverse effects at a CBD concentration of 100 mg/mL, within a dose range of 50 mg to 600 mg per day, in 2 weeks [138].”
The authors apologize for any inconvenience caused and state that the conclusions of the original article have been unaffected. The original publication has been updated.